Phase II Study of Amrubicin and Nitroglycerin in Third-Line Chemotherapy in Previously Treated Patients with Non-Small-Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Previously treated non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000000813
- Lead Sponsor
- Division of Clinical Trial Design and Management, Translational Clinical Center, Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
(a)No treatment with a vasodilator such as calcium channel blockers; (b)No treatment with nitric oxide donationg drugs; (c)No prior chemotherapy using amrubicin; (d)No radiotherapy to evaluable tumor lesions during this protocol treatment (e)Without brain metastasis; (f)No unstable ischemic heart disease; (g)No active hepatitis; (h)No active interstitial pneumonitis; (i)No active hematological disease such as leukemia; (j)No incurable duplicative cancers; (k)No uncontrollable psychological disease; (l)No female under nursing or pregnancy (m)No enrollment in another interventional study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method